Real-world data of subcutaneous trastuzumab and intravenous pertuzumab as neoadjuvant therapy for localized HER2+ breast cancer in Panama | Zendy

Franklin Castillero | Zendy; O. Castillo | Zendy; Maria Lim-Law | Zendy; Cristiane Martin Palacios | Zendy; Lilian Montano | Zendy; Stephanie Benitez | Zendy; Jaime Samudio | Zendy

Open Access

Real-world data of subcutaneous trastuzumab and intravenous pertuzumab as neoadjuvant therapy for localized HER2+ breast cancer in Panama

Author(s) -

Franklin Castillero,

O. Castillo,

Maria Lim-Law,

Cristiane Martin Palacios,

Lilian Montano,

Stephanie Benitez,

Jaime Samudio

Publication year - 2021

Publication title -

breast cancer management

Language(s) - English

Resource type - Journals

eISSN - 1758-1931

pISSN - 1758-1923

DOI - 10.2217/bmt-2021-0003

Subject(s) - pertuzumab , trastuzumab , medicine , breast cancer , oncology , pathological , immunohistochemistry , blockade , neoadjuvant therapy , retrospective cohort study , chemotherapy , cancer , receptor

The aim of this study is to determine the effectiveness of subcutaneous trastuzumab in combination with intravenous pertuzumab and chemotherapy for patients with HER2-overexpressing localized breast cancer treated in our center. Methods: This was a descriptive, retrospective, real-world study. Results: Of 156 patients, pathological complete response (pCR) was achieved in 64.1%. A multivariate analysis showed a relationship with a negative hormone receptor (HR) expression and a HER2 score of 3+ by immunohistochemistry. Relapse-free survival (RFS) was higher in patients with pCR. Conclusion: Neoadjuvant therapy with dual blockade using intravenous pertuzumab and subcutaneous trastuzumab for HER2+ localized breast cancer in routine clinical practice resulted in a 64.1% pCR rate. Additionally, this outcome was related to a negative HR expression and HER2 overexpression, and correlated with higher relapse-free survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research